Takeda

Clarithromycin (CLARITHRO 250) is an oral small-molecule antibiotic being investigated by Takeda for multiple myeloma treatment in a Phase 2 clinical program (internal code 728937). The drug is a macrolide antibiotic with established regulatory approval in multiple markets including Australia (since 1999), the United States (multiple generic and branded formulations), and China (clinical trials ongoing). Clarithromycin's mechanism of action in myeloma and specific molecular target are not yet disclosed. The program's latest milestone was recorded on 19 September 2024, though specific details of that milestone remain undisclosed. The drug is currently in active development status with one primary clinical trial identifier (NCT02542657) associated with the myeloma indication. Clarithromycin has an extensive approval history as an antibacterial agent across multiple jurisdictions, with numerous generic manufacturers holding approvals in the United States and Australia, suggesting established manufacturing and regulatory pathways that may facilitate development in new indications.

Multiple myeloma remains a disease with significant unmet medical need despite recent therapeutic advances. While proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies have improved outcomes, patients continue to face disease progression, treatment resistance, and cumulative toxicity. Repositioning clarithromycin—an established, well-tolerated oral antibiotic with decades of safety data—for myeloma represents a potential strategy to identify new therapeutic applications for existing drugs, potentially offering cost advantages and rapid clinical development pathways compared to de novo drug discovery.

The competitive myeloma landscape includes multiple approved agents such as bortezomib, lenalidomide, pomalidomide, ixazomib, and isatuximab, as well as emerging therapies in Phase 3 development. Clarithromycin's oral route of administration and established safety profile could differentiate it if efficacy is demonstrated, particularly for patients requiring convenient dosing or those with contraindications to existing therapies. The patient population for myeloma is substantial and growing, with significant commercial opportunity for agents that improve outcomes or reduce treatment burden. However, the mechanism by which clarithromycin exerts anti-myeloma activity remains undisclosed, making assessment of its true competitive positioning premature.

Drug Class: Macrolide antibiotic; small-molecule oral formulation

Modality: Small molecule

Route of Administration: Oral

Mechanism of Action: Not yet disclosed for myeloma indication

Molecular Target: Not yet disclosed for myeloma indication

Brand Name: CLARITHRO 250

International Nonproprietary Name (INN): Clarithromycin

Regulatory Status (Established Indication—Bacterial Infection):

• Australia: Approved since 1999 (PBS codes 8318T, 9192T); multiple sponsors including Alphapharm Pty Ltd, Arrow Pharma Pty Ltd, Sandoz Pty Ltd, and Viatris Pty Ltd
• United States: Approved; multiple generic manufacturers hold ANDAs and NDAs including AbbVie, Teva, Sandoz, Lupin, Dr. Reddy's Labs, Aurobindo, and others
• China: Clinical trials ongoing (NCT07439445)

Related Therapies in Myeloma: Bortezomib, lenalidomide, pomalidomide, ixazomib, isatuximab, tocilizumab, ibrutinib, and melphalan hydrochloride

Clarithromycin (Established Bacterial Indication):

• United States (FDA): Approved; multiple generic manufacturers hold abbreviated new drug applications (ANDAs) and new drug applications (NDAs). Application numbers include ANDA065136, ANDA065137, ANDA065144, ANDA065145, ANDA065154, ANDA065155, ANDA065174, ANDA065178, ANDA065195, ANDA065210, ANDA065250, ANDA065266, ANDA065283, ANDA065382, ANDA065384, ANDA065489, ANDA202532, ANDA202710, ANDA203243, ANDA203584, ANDA206714, ANDA208987, ANDA210459, NDA050662, NDA050697, NDA050698, and NDA050775. Sponsors include AbbVie, Teva, Sandoz, Lupin, Dr. Reddy's Labs, Aurobindo, Chartwell, Hikma, Jubilant Cadista, MPP Pharma, Novitium Pharma, Pharmobedient, Ranbaxy, Sun Pharma, Sunshine, and Wockhardt.
• Australia (TGA): Approved since 1999; PBS-listed with codes 8318T and 9192T. Multiple sponsors hold approvals: Alphapharm Pty Ltd (first listed 1 May 1999), Arrow Pharma Pty Ltd (first listed 4 December 2004), Sandoz Pty Ltd (first listed 1 August 2006), and Viatris Pty Ltd.
• China (NMPA): Clinical trials ongoing; NCT07439445 registered.
• European Medicines Agency (EMA): Regulatory status not yet disclosed.
• Japan (PMDA): Regulatory status not yet disclosed.

Myeloma Indication (Takeda Program): Regulatory pathway and expected timelines not yet disclosed. Phase 2 status indicates investigational stage.

Strategic Implications: Takeda's investigation of clarithromycin for myeloma represents a drug repurposing strategy leveraging an established, well-tolerated agent with extensive safety data and established manufacturing. This approach may accelerate development timelines and reduce regulatory risk compared to novel chemical entities. However, the undisclosed mechanism of action raises questions about the scientific rationale and potential competitive advantage.

Development Status and Catalysts: The program remains in Phase 2 with a latest milestone on 19 September 2024, though specific details are not disclosed. Key future catalysts include: (1) disclosure of Phase 2 efficacy and safety data; (2) advancement to Phase 3 if warranted; (3) clarification of mechanism of action and molecular target; (4) regulatory guidance on development pathway; and (5) competitive positioning relative to approved and emerging myeloma therapies.

Competitive Positioning: Clarithromycin's oral route and established safety profile could offer advantages in specific patient populations. However, the myeloma market is crowded with multiple approved agents and numerous Phase 3 programs. Differentiation will depend on demonstrated efficacy, tolerability profile, and potential for use in combination regimens. The lack of disclosed mechanism limits assessment of true competitive advantage.

Risk Factors: Phase 2 status indicates substantial development risk. The mechanism of action for myeloma remains undisclosed, creating uncertainty about scientific rationale. Competitive pressure from established and emerging therapies is significant. Regulatory pathway for a new indication in an established drug requires demonstration of efficacy and safety in the target population.